Diabetes Drugs: Medicare Part D Spending

• 34medicines with Part D spending (calendar year 2024)

Each number has its full source under its own list below.

1. 1FarxigaDapagliflozin Propanediol · $18.31 per unit$5.3 billion
2. 2Victoza 3-PakLiraglutide · $86.21 per unit$203.1 million
3. 3DapagliflozinDapagliflozin Propanediol · $16.24 per unit$201.9 million
4. 4PregabalinPregabalin · $0.31 per unit$199.2 million
5. 5Metformin HClMetformin HCl · $0.06 per unit$188.1 million
6. 6Metformin HCl ERMetformin HCl · $0.06 per unit$101.5 million
7. 7Metformin ER GastricMetformin HCl · $12.37 per unit$85.9 million
8. 8Victoza 2-PakLiraglutide · $91.45 per unit$77.8 million
9. 9LyricaPregabalin · $9.67 per unit$62 million
10. 10Sandostatin Lar DepotOctreotide Acetate,Mi-Spheres · $5,143.25 per unit$56.5 million
11. 11LiraglutideLiraglutide · $75.15 per unit$48.1 million
12. 12Glipizide ERGlipizide · $0.15 per unit$47.2 million
13. 13GlipizideGlipizide · $0.08 per unit$43.2 million
14. 14Pioglitazone HClPioglitazone HCl · $0.18 per unit$42.4 million
15. 15GlimepirideGlimepiride · $0.09 per unit$41.4 million

Source: Centers for Medicare & Medicaid Services, Medicare Part D Spending by Drug, calendar year 2024. Retrieved 12 Nov 2026.

• Diabetes (ages 20–79)
• Diabetes (adults, WHO)
• Clinical trials: Diabetes
• Diabetes death rate

• Obesity
• Cardiovascular
• Eye health
• Hypertension
• Kidney health
• Maternal
• HIV
• Tuberculosis
• Pediatric